公开(公告)号：US09453063B2

公开(公告)日：2016-09-27

申请号：US14195262

申请日：2014-03-03

申请人： Amylin Pharmaceuticals, LLC ,  Astrazeneca Pharmaceuticals LP

发明人： Odile Esther Levy ,  Michael R. Hanley ,  Carolyn M. Jodka ,  Diana Y. Lewis ,  Christopher J. Soares ,  Soumitra S. Ghosh ,  Lawrence J. D'Souza ,  David G. Parkes ,  Christine M. Mack

IPC分类号： A61K38/26 ,  C07K14/605 ,  C07K5/103 ,  C07K5/117 ,  C07K14/575 ,  C07K14/58 ,  A61K9/00 ,  A61K9/19 ,  A61K38/00

CPC分类号： C07K14/605 ,  A61K9/0019 ,  A61K9/19 ,  A61K38/00 ,  C07K5/1013 ,  C07K5/1024 ,  C07K14/575 ,  C07K14/58

摘要： The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

公开(公告)号：US20140249076A1

公开(公告)日：2014-09-04

申请号：US14352087

申请日：2012-10-17

申请人： AMYLIN PHARMACEUTICALS, LLC ,  ASTRAZENECA PHARMACEUTICALS LP

发明人： Manoj P. Samant ,  Ved Srivastava ,  Odile Esther Levy ,  Christine M. Mack ,  William E. Rote

IPC分类号： A61K47/48

CPC分类号： A61K47/48215 ,  A61K47/60 ,  C07K14/585

摘要： Provided herein are amylin-calcitonin peptide conjugates having enhanced duration of biological activity, and methods of use thereof. The amylin-calcitonin peptide conjugates include duration enhancing moieties, such as water soluble polymers and long chain aliphatic groups, bound to the amylin-calcitonin peptide. Methods of use are provided for treatment of an eating disorder, insulin resistance, obesity, overweight, abnormal postprandial hyperglycemia, Type I diabetes, Type II diabetes, gestational diabetes, metabolic syndrome, dumping syndrome, hypertension, dyslipidemia, cardiovascular disease, hyperlipidemia, sleep apnea, cancer, pulmonary hypertension, cholescystitis or osteoarthritis.

摘要翻译： 本文提供了具有增强的生物活性持续时间的胰岛淀粉样多肽 - 降钙素肽缀合物及其使用方法。 胰岛淀粉样多肽降钙素肽缀合物包括与胰岛淀粉样多肽降钙素肽结合的持续时间增强部分，例如水溶性聚合物和长链脂族基团。 提供使用方法用于治疗进食障碍，胰岛素抵抗，肥胖，超重，餐后异常高血糖症，I型糖尿病，II型糖尿病，妊娠糖尿病，代谢综合征，倾倒综合征，高血压，血脂异常，心血管疾病，高脂血症，睡眠 呼吸暂停，癌症，肺动脉高压，胆囊炎或骨关节炎。

公开(公告)号：US20130196913A1

公开(公告)日：2013-08-01

申请号：US13849933

申请日：2013-03-25

申请人： Amylin Pharmaceuticals, LLC ,  AstraZeneca Pharmaceuticals LP

发明人： Odile Esther Levy ,  Alain D. Baron ,  Lawrence J. D'Souza ,  Mary Erickson ,  Soumitra S. Ghosh ,  Michael R. Hanley ,  Samuel Janssen ,  Carolyn M. Jodka ,  Diana Y. Lewis ,  Christine M. Mack ,  David G. Parkes ,  Richard A. Pittner ,  Christopher J. Soares ,  Ved Srivastava ,  Andrew A. Young

IPC分类号： C07K14/575

CPC分类号： C07K14/575 ,  C07K14/605 ,  C07K2319/00

摘要： The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

公开(公告)号：US20140249299A1

公开(公告)日：2014-09-04

申请号：US14195262

申请日：2014-03-03

申请人： AstraZeneca Pharmaceuticals LP ,  Amylin Pharmaceuticals, LLC

发明人： Odile Esther Levy ,  Michael R. Hanley ,  Carolyn M. Jodka ,  Diana Y. Lewis ,  Christopher J. Soares ,  Soumitra S. Ghosh ,  Lawrence J. D'Souza ,  David G. Parkes ,  Christine M. Mack

IPC分类号： C07K14/575 ,  C07K14/605

CPC分类号： C07K14/605 ,  A61K9/0019 ,  A61K9/19 ,  A61K38/00 ,  C07K5/1013 ,  C07K5/1024 ,  C07K14/575 ,  C07K14/58

摘要： The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

摘要翻译： 本发明一般涉及可用作治疗和预防代谢性疾病和病症的新颖的可选择的杂交多肽，其可通过控制血浆葡萄糖水平，胰岛素水平和/或胰岛素分泌而减轻，所述胰岛素分泌如糖尿病和糖尿病相关 条件。 这些病症和障碍包括但不限于高血压，血脂异常，心血管疾病，进食障碍，胰岛素抵抗，肥胖症和任何类型的包括1型，2型和妊娠糖尿病的糖尿病。

公开(公告)号：US20130281374A1

公开(公告)日：2013-10-24

申请号：US13868891

申请日：2013-04-23

申请人： AstraZeneca Pharmaceuticals LP ,  Amylin Pharmaceuticals, LLC

发明人： Odile Esther Levy ,  Alain D. Baron ,  Lawrence J. D'Souza ,  Mary Erickson ,  Soumitra S. Ghosh ,  Michael R. Hanley ,  Samuel Janssen ,  Carolyn M. Jodka ,  Diana Y. Lewis ,  Christine M. Mack ,  David G. Parkes ,  Richard A. Pittner ,  Christopher J. Soares ,  Ved Srivastava ,  Andrew A. Young ,  Thao Le

IPC分类号： C07K14/47

CPC分类号： C07K14/47 ,  A61K38/00 ,  C07K14/575 ,  C07K14/57563 ,  C07K14/605 ,  C07K2319/00

摘要： The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

摘要翻译： 本发明一般涉及具有可选性质的新型GIP类似物和GIP杂合多肽，其可用作治疗和预防代谢性疾病和病症的药剂，例如可通过控制血浆葡萄糖水平，胰岛素水平和/或 胰岛素分泌，正性肌力作用，分解代谢作用降低，胃排空减慢。 这些病症和障碍包括但不限于高血压，血脂异常，心血管疾病，饮食失调，重症监护，胰岛素抵抗，肥胖症和任何类型的糖尿病，包括1型，2型和妊娠糖尿病。

公开(公告)号：US09133260B2

公开(公告)日：2015-09-15

申请号：US13849933

申请日：2013-03-25

申请人： Amylin Pharmaceuticals, LLC ,  AstraZeneca Pharmaceuticals LP

发明人： Odile Esther Levy ,  Alain D. Baron ,  Lawrence J. D'Souza ,  Mary Erickson ,  Soumitra S. Ghosh ,  Michael R. Hanley ,  Samuel Janssen ,  Carolyn M. Jodka ,  Diana Y. Lewis ,  Christine M. Mack ,  David G. Parkes ,  Richard A. Pittner ,  Christopher J. Soares ,  Ved Srivastava ,  Andrew A. Young

IPC分类号： A61K38/00 ,  A61P3/10 ,  C07K14/575 ,  C07K14/605

CPC分类号： C07K14/575 ,  C07K14/605 ,  C07K2319/00

摘要： The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

摘要翻译： 本发明一般涉及具有可选性质的新型GIP类似物和GIP杂合多肽，其可用作治疗和预防代谢性疾病和病症的药剂，例如可通过控制血浆葡萄糖水平，胰岛素水平和/或 胰岛素分泌，正性肌力作用，分解代谢作用降低，胃排空减慢。 这些病症和障碍包括但不限于高血压，血脂异常，心血管疾病，饮食失调，重症监护，胰岛素抵抗，肥胖症和任何类型的糖尿病，包括1型，2型和妊娠糖尿病。

公开(公告)号：US08906849B2

公开(公告)日：2014-12-09

申请号：US13858398

申请日：2013-04-08

申请人： Amylin Pharmaceuticals, LLC ,  AstraZeneca Pharmaceuticals LP

发明人： Odile Esther Levy ,  Carolyn M. Jodka ,  Soumitra S. Ghosh ,  David G. Parkes ,  Richard A. Pittner ,  Lawrence J. D'Souza ,  John S. Ahn ,  Kathryn S. Prickett ,  Jonathan David Roth ,  Sean H. Adams

IPC分类号： A61K38/00 ,  A61P3/04 ,  C07K14/575 ,  C07K14/475

CPC分类号： C07K14/575 ,  A61K38/00 ,  C07K14/475

摘要： The present invention provides novel Pancreatic Polypeptide Family (“PPF”) polypeptides and methods for their use.

摘要翻译： 本发明提供了新型胰腺多肽家族（“PPF”）多肽及其使用方法。